These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 20015155)

  • 1. Macromolecular drug transport into the brain using targeted therapy.
    Lichota J; Skjørringe T; Thomsen LB; Moos T
    J Neurochem; 2010 Apr; 113(1):1-13. PubMed ID: 20015155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
    Löscher W; Potschka H
    Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential receptor-mediated drug targeting to the diseased brain.
    Rip J; Schenk GJ; de Boer AG
    Expert Opin Drug Deliv; 2009 Mar; 6(3):227-37. PubMed ID: 19327042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons.
    Kleine TO; Benes L
    Cytometry A; 2006 Mar; 69(3):147-51. PubMed ID: 16479603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
    Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
    Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers.
    Ganta S; Deshpande D; Korde A; Amiji M
    Mol Membr Biol; 2010 Oct; 27(7):260-73. PubMed ID: 20929336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.
    Vlieghe P; Khrestchatisky M
    Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
    Shen DD; Artru AA; Adkison KK
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1825-57. PubMed ID: 15381336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug targeting to the brain.
    de Boer AG; Gaillard PJ
    Annu Rev Pharmacol Toxicol; 2007; 47():323-55. PubMed ID: 16961459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The blood-brain barrier. II. Physiological data].
    Lefauconnier JM; Hauw JJ
    Rev Neurol (Paris); 1984; 140(1):3-13. PubMed ID: 6364292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The blood-brain barrier and drug delivery in the central nervous system].
    Loch-Neckel G; Koepp J
    Rev Neurol; 2010 Aug; 51(3):165-74. PubMed ID: 20645267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental aspects of blood-brain barrier (BBB) and rat brain endothelial (RBE4) cells as in vitro model for studies on chlorpyrifos transport.
    Yang J; Aschner M
    Neurotoxicology; 2003 Aug; 24(4-5):741-5. PubMed ID: 12900088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier and treatment of central nervous system tumors.
    Wiranowska M
    J Fla Med Assoc; 1992 Oct; 79(10):707-10. PubMed ID: 1460453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases.
    Gabathuler R
    Neurobiol Dis; 2010 Jan; 37(1):48-57. PubMed ID: 19664710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system.
    Allen DD; Geldenhuys WJ
    Life Sci; 2006 Feb; 78(10):1029-33. PubMed ID: 16126231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detoxification systems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations.
    Strazielle N; Khuth ST; Ghersi-Egea JF
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1717-40. PubMed ID: 15381331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
    Juillerat-Jeanneret L
    Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations.
    Lee G; Dallas S; Hong M; Bendayan R
    Pharmacol Rev; 2001 Dec; 53(4):569-96. PubMed ID: 11734619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide and peptide analog transport systems at the blood-CSF barrier.
    Smith DE; Johanson CE; Keep RF
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1765-91. PubMed ID: 15381333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.